Clicky

Catalyst Inc.(CBIO)

Description: Catalyst Biosciences, Inc., a biopharmaceutical company, focuses on discovering and developing novel biopharmaceutical products based on engineered human proteases. The company designs its proteases to promote hemostasis and to prevent inflammation. Its pipeline of protease therapeutics include CB 813d/PF-05280602, an engineered Factor VIIa drug candidate that completed a Phase 1 clinical trial evaluating safety and tolerability, as well as pharmacokinetics, pharmacodynamics, and coagulation activity. The company's pre-clinical development stage drugs comprise CB 2679d/ISU 304, a next-generation Factor IX drug for the treatment of hemophilia B inhibitor patients; and an engineered Factor Xa for hemophilia and the control of bleeding in non-hemophilia patients. It also develops factor C3 for the prevention of renal delayed graft function and the treatment of dry age-related macular degeneration. Catalyst Biosciences, Inc. is headquartered in South San Francisco, California.


Keywords: Biopharmaceutical Pharmaceutical Products Inflammation Molecular Biology Cell Biology Clinical Development Macular Degeneration Pharmacokinetics Hemophilia Biopharmaceutical Products Coagulation Coagulation System Hemophilia A Hemostasis Treatment Of Hemophilia Dry Age Related Macular Degeneration Pharmacodynamics Hemophilia B

Home Page: www.catalystbiosciences.com

CBIO Technical Analysis

611 Gateway Boulevard
South San Francisco, CA 94080
United States
Phone: 650 871 0761


Officers

Name Title
Dr. Nassim Usman Ph.D. Pres, CEO & Director
Ms. Seline E. Miller CPA Sr. VP of Fin., Interim Chief Financial & Principal Accounting Officer
Dr. Grant Blouse M.Sc., Ph.D. Chief Scientific Officer
Ms. Ana Kapor Sr. Director of Investor Relations & Corp. Communications
Dr. Tom Knudsen D.V.M., Ph.D. Sr. VP of Corp. Devel.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 1.529
Price-to-Book MRQ: 0.5274
Price-to-Sales TTM: 4.8219
IPO Date: 2006-04-12
Fiscal Year End: December
Full Time Employees: 45
Back to stocks